Table 2.

Treatment goal preference weights in the clinical versus functional focused segments^a

Treatment goals	Mean,b %	SD	p-value
Reduced frequency of disease symptoms (hallucinations, delusions, etc.)			<0.001
Clinical	19.7	3.4
Functional	10.1	5.9
Reduced hospitalizations due to relapse of disease symptoms			<0.001
Clinical	15.5	5.3
Functional	4.6	3.9
Improved ability to think clearly			0.685
Clinical	12.3	5.6
Functional	11.9	5.1
Reduced anxiety (worry, stress, and agitation)			0.035
Clinical	10.5	4.1
Functional	8.6	4.9
Increased ability to take care of self (being independent, able to cook, clean, etc.)			0.065
Clinical	10.4	5.7
Functional	8.3	5.5
Improved ability to experience a fuller range of happy and sad emotions			<0.001
Clinical	5.0	3.6
Functional	8.4	4.2
Improved relationships with my family and friends			<0.001
Clinical	4.6	3.9
Functional	11.4	5.1
Reduced sexual problems (sex drive, intimacy, sexual functioning)			0.927
Clinical	4.3	5.3
Functional	4.2	5.4
Reduced instances of restlessness or urges to move			0.883
Clinical	4.0	3.8
Functional	4.2	3.3
Reduced frequency of feeling too tired or slowed down			0.073
Clinical	3.9	3.3
Functional	5.3	4.6
Reduced risk of weight gain			0.235
Clinical	3.6	5.6
Functional	5.0	6.1
Increased interest in hobbies, studies, or work			<0.001
Clinical	3.5	3.4
Functional	10.6	6.2
Improved ability to socialize and talk with others			<0.001
Clinical	2.8	2.2
Functional	7.5	3.9

Notes:

^aClinical focused group (N=50) and functional focused group (N=50).

^bRatio data (10% is twice as important as 5%); sum of preference weights is 100% within each segment.